Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) Net Income towards Common Stockholders (2023 - 2025)

Historic Net Income towards Common Stockholders for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to -$27.1 million.

  • Monte Rosa Therapeutics' Net Income towards Common Stockholders fell 1350.43% to -$27.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.9 million, marking a year-over-year increase of 11751.67%. This contributed to the annual value of -$72.7 million for FY2024, which is 4626.6% up from last year.
  • Per Monte Rosa Therapeutics' latest filing, its Net Income towards Common Stockholders stood at -$27.1 million for Q3 2025, which was down 1350.43% from -$12.3 million recorded in Q2 2025.
  • In the past 5 years, Monte Rosa Therapeutics' Net Income towards Common Stockholders registered a high of $46.9 million during Q1 2025, and its lowest value of -$35.2 million during Q2 2023.
  • Its 3-year average for Net Income towards Common Stockholders is -$18.2 million, with a median of -$30.3 million in 2024.
  • Within the past 5 years, the most significant YoY rise in Monte Rosa Therapeutics' Net Income towards Common Stockholders was 24658.43% (2025), while the steepest drop was 1350.43% (2025).
  • Monte Rosa Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$33.3 million in 2023, then soared by 140.32% to $13.4 million in 2024, then crashed by 301.99% to -$27.1 million in 2025.
  • Its Net Income towards Common Stockholders was -$27.1 million in Q3 2025, compared to -$12.3 million in Q2 2025 and $46.9 million in Q1 2025.